Raffa R B, Friderichs E, Reimann W, Shank R P, Codd E E, Vaught J L
R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477-0776.
J Pharmacol Exp Ther. 1992 Jan;260(1):275-85.
Tramadol hydrochloride produced dose-related antinociception in mouse abdominal constriction [ED50 = 1.9 (1.2-2.6) mg/kg i.p.], hot-plate [48 degrees C, ED50 = 21.4 (18.4-25.3) mg/kg s.c.; 55 degrees C, ED50 = 33.1 (28.2-39.1) mg/kg s.c.] and tail-flick [ED50 = 22.8 (19.2-30.1) mg/kg s.c.] tests. Tramadol also displayed antinociceptive activity in the rat air-induced abdominal constriction [ED50 = 1.7 (0.7-3.2) mg/kg p.o.] and hot-plate [51 degrees C, ED50 = 19.5 (10.3-27.5) mg/kg i.p.] tests. The antinociceptive activity of tramadol in the mouse tail-flick test was completely antagonized by naloxone, suggesting an opioid mechanism of action. Consistent with this, tramadol bound with modest affinity to opioid mu receptors and with weak affinity to delta and kappa receptors, with Ki values of 2.1, 57.6 and 42.7 microM, respectively. The pA2 value for naloxone obtained with tramadol in the mouse tail-flick test was 7.76 and was not statistically different from that obtained with morphine (7.94). In CXBK mice, tramadol, like morphine, was devoid of antinociceptive activity after intracerebroventricular administration, suggesting that the opioid component of tramadol-induced antinociception is mediated by the mu-opioid receptor. In contrast to the mouse tail-flick test and unlike morphine or codeine, tramadol-induced antinociception in the mouse abdominal constriction, mouse hot-plate (48 degrees or 55 degrees C) or rat hot-plate tests was only partially antagonized by naloxone, implicating a nonopioid component. Further examination of the neurochemical profile of tramadol revealed that, unlike morphine, it also inhibited the uptake of norepinephrine (Ki = 0.79 microM) and serotonin (0.99 microM). The possibility that this additional activity contributes to the antinociceptive activity of tramadol was supported by the finding that systemically administered yohimbine or ritanserin blocked the antinociception produced by intrathecal administration of tramadol, but not morphine, in the rat tail-flick test. These results suggest that tramadol-induced antinociception is mediated by opioid (mu) and nonopioid (inhibition of monoamine uptake) mechanisms. This hypothesis is consistent with the clinical experience of a wide separation between analgesia and typical opioid side effects.
盐酸曲马多在小鼠腹部收缩试验[半数有效量(ED50)=1.9(1.2 - 2.6)mg/kg,腹腔注射]、热板试验[48℃时,ED50 = 21.4(18.4 - 25.3)mg/kg,皮下注射;55℃时,ED50 = 33.1(28.2 - 39.1)mg/kg,皮下注射]和甩尾试验[ED50 = 22.8(19.2 - 30.1)mg/kg,皮下注射]中产生剂量相关的抗伤害感受作用。曲马多在大鼠空气诱发的腹部收缩试验[ED50 = 1.7(0.7 - 3.2)mg/kg,口服]和热板试验[51℃时,ED50 = 19.5(10.3 - 27.5)mg/kg,腹腔注射]中也表现出抗伤害感受活性。曲马多在小鼠甩尾试验中的抗伤害感受活性被纳洛酮完全拮抗,提示其作用机制为阿片样物质机制。与此一致的是,曲马多对阿片μ受体具有适度亲和力,对δ和κ受体具有弱亲和力,其抑制常数(Ki)值分别为2.1、57.6和42.7微摩尔。在小鼠甩尾试验中,曲马多与纳洛酮联用得到的拮抗参数(pA2)值为7.76,与吗啡(7.94)得到的值无统计学差异。在CXBK小鼠中,与吗啡一样, 曲马多经脑室注射后无抗伤害感受活性,提示曲马多诱导的抗伤害感受的阿片样物质成分是由μ-阿片受体介导的。与小鼠甩尾试验不同,且与吗啡或可待因不同,曲马多在小鼠腹部收缩试验、小鼠热板试验(48℃或55℃)或大鼠热板试验中诱导的抗伤害感受仅被纳洛酮部分拮抗,提示存在非阿片样物质成分。对曲马多神经化学特征的进一步研究表明,与吗啡不同,它还抑制去甲肾上腺素(Ki = 0.79微摩尔)和5-羟色胺(0.99微摩尔)的摄取。在大鼠甩尾试验中,全身给予育亨宾或利坦色林可阻断鞘内注射曲马多而非吗啡产生的抗伤害感受,这一发现支持了这种额外活性有助于曲马多抗伤害感受活性的可能性。这些结果表明,曲马多诱导的抗伤害感受是由阿片样物质(μ)和非阿片样物质(抑制单胺摄取)机制介导的。这一假说与镇痛和典型阿片样物质副作用之间存在较大差异的临床经验相符。